▼ SELL
10b5-1 Plan
$ Value
$50K
Shares
10,000
Price
$5
Filed
Dec 2
Insider
Name
Thomas John
Title
—
CIK
0001939103
Roles
Director
Transaction Details
Transaction Date
2025-12-01
Code
S
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
492,784
Footnotes
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025. | The weighted average sale price for the transaction reported was $5.0008, and the range of prices were between $4.73 and $5.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Filing Info
Thomas John's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-02 | GNLX | ▼ | $29K |
| 2025-12-01 | GNLX | ▼ | $50K |
| 2025-08-27 | GNLX | A | $0 |
| 2025-08-27 | GNLX | A | $0 |
| 2025-06-06 | GNLX | G | $0 |
Other Insiders at GNLX (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Yu Yong / Cappello Joseph
SVP, Clinical Development
|
— | $2K | 2026-03-24 |
|
Zindrick Thomas
President and CEO
|
— | $9K | 2026-03-24 |
| Thomas John | — | $29K | 2026-03-02 |
|
Smalling Ralph
Head of Regulatory
|
— | $1K | 2026-03-25 |